DAVID BIANCULLI

Founder / Editor

ERIC GOULD

Associate Editor

LINDA DONOVAN

Assistant Editor

Contributors

ALEX STRACHAN

MIKE HUGHES

KIM AKASS

MONIQUE NAZARETH

ROGER CATLIN

GARY EDGERTON

TOM BRINKMOELLER

GERALD JORDAN

NOEL HOLSTON

 
 
 
 
 
The Web of Deceit, Bribery, and Greed is Brought to Light with 'Opioids, Inc.' on PBS
June 23, 2020  | By David Hinckley  | 6 comments
 


The COVID-19 pandemic has temporarily overshadowed what remains an even more lethal ongoing health crisis: the opioids epidemic that has claimed more than half a million lives in America since 1999.

It’s not a competition. But PBS’s Frontline offers a sobering documentary at 9 p.m. ET Tuesday (check local listings), titled Opioids, Inc., that reminds us how sometimes it’s not only the physical adversary with which victims must contend.

Opioids, Inc. traces the path of Insys Therapeutics, a drug company that began by doing something admirable: formulating an easily used spray form of an extremely powerful medication that could ease pain in late-stage cancer patients.

The company’s founder, John Kapoor, had begun searching for that kind of drug after his wife died of cancer. He turned to fentanyl, a drug 50 times more potent than morphine, and had his technicians rework it into spray form – which kicked in almost immediately, making it a godsend to sufferers and their loved ones.

An investigation by Frontline and the Financial Times discovered, however, that John Kapoor was equally obsessed with something else: making lots of money, like billions of dollars, from this drug.

He hired a sales chief whose game plan was to ignore any rulebook for selling medical material. Instead, Insys began bribing doctors, paying them large sums of money to speak at medical conferences, that may or may not have been bogus, in return for those doctors steering patients toward Insys products.

And not just Insys products, but ever-higher doses of Insys products. Higher doses sold for more money and thus meant higher profits for Insys, so sales reps and doctors were rewarded on a sliding scale. Get a patient up to the maximum dose, and everyone made money.

Opioids, Inc. does not talk to patients or their families, so we don’t meet any individuals who may not have needed the dosage their doctors recommended.

But just the fact Insys established that system compromised medical integrity. It also defrauded insurance companies, which is why Dr. Kapoor was charged, convicted, and sentenced to five and a half years in prison. He is currently appealing that sentence, which is why his attorneys said he would not be available for the documentary.

The people to whom filmmaker Tom Jennings does talk, however, are pretty candid about the Insys system, particularly from the sales side. Bribing doctors? Sure, that’s precisely what they were pushed to do.

Nor were drug sales even the primary profit center for Kapoor. That was Wall Street. As the popularity of Insys drugs seemed to soar, Insys went public, and its stock price soared, as well. Kapoor’s original $80 million investment had given him a paper value of more than a billion dollars before it all came crashing down.

At least one of Kapoor’s doctors tells Jennings that she remains conflicted. His original achievement of finding a better pain medication for terminal cancer patients, she said, remains admirable and legitimate. The subsequent greed, not so much.

Opioids, Inc. focuses solely on the Insys case, leaving viewers to draw their own conclusions about the larger issue: to what extent America’s opioids crisis could have been at least mitigated if there weren’t so much money to be made and enough people up the whole medical chain hadn’t been so eager to make it.

 
 
 
 
 
Leave a Comment: (No HTML, 1000 chars max)
 
 Name (required)
 
 Email (required) (will not be published)
 
TPJFM
Type in the verification word shown on the image.
 
 
 Page: 1 of 1  | Go to page: 
6 Comments
 
 
Saephanch
I need an advice. I am currently processing a crypto recovery,with an agency called, Email: alliancedigitalrecovery@outlook.com
Whatsapp: +44 7452 247277 and we did some transaction validation. Out of 200k USD which was lost they where able to recover 90% of my lost, and I have only received only 60k USD and its been four days already since we started. I am a bit worried, i will like to know if they took the remaining of my money or if it is actually impossible to recover entirely everything i lost?
Aug 27, 2024   |  Reply
 
 
Cryptocurrencies transcend national borders and offer solutions for cross-border transactions and remittances. In countries with unstable currencies or restrictive financial systems, cryptocurrencies provide a viable alternative for individuals and businesses.
Jul 18, 2024   |  Reply
 
 
Our product will help you improve your productivity, lessen your budget in maintenance and repair. In selling machining inserts, We will make sure that you will get enough profit in our products.
May 31, 2024   |  Reply
 
 
We shares the passion for this industry in the most advanced way. We provide machining inserts and other products that match the ambitions and goals of your company. We assures you that our machining inserts are tested carefully in quality, repeatability, customer service, and production versatility., welcome to our website to learn more about carbide inserts:https://www.estoolcarbide.com
Mar 27, 2024   |  Reply
 
 
Professional know-how technicians, advanced manufacturing technology, strict testing standard to ensure performance of every piece., welcome to our website to learn more about carbide inserts:https://www.estoolcarbide.com
Mar 1, 2024   |  Reply
 
 
As a professional manufacturer, Estool offer the best cutting tools solution throughout a diverse product portfolio. Estool is dedicated to providing full services, from research and development, production, marketing to exporting. With more than 10 years of experience, Estool had established a perfect management system., welcome to our website to learn more about carbide inserts:https://www.estoolcarbide.com
Jan 29, 2024   |  Reply
 
 
 
 Page: 1 of 1  | Go to page: